Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML

Phase 2

Active, not recruiting

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia

Interventions: Drug: etoposide
Drug: cyclophosphamide
Radiation: total marrow irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: allogeneic bone marrow transplantation

First Posted Date: 2014-03-24

Last Posted Date: 2024-12-03

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 108

Registration Number: NCT02094794

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: ixazomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2014-02-25

Last Posted Date: 2018-12-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT02070458

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Carmustine
Drug: Etoposide
Drug: Melphalan
Drug: Cytarabine
Drug: Alemtuzumab
Biological: Autologous Stem Cell Transplantation
Biological: Allogeneic Stem Cell Transplantation
Drug: Rituximab

First Posted Date: 2014-02-11

Last Posted Date: 2021-02-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 34

Registration Number: NCT02059239

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Phase 2

Terminated

Conditions: Acute Lymphocytic Leukemia
Adult Lymphoblastic Lymphoma

Interventions: Drug: DNR
Drug: VCR
Drug: PEG-asp
Drug: CTX
Drug: Prednisone
Drug: Liposomal AraC
Drug: MTX
Drug: LCV
Drug: AraC
Drug: Etoposide
Drug: Dasatinib
Drug: Rituximab
Drug: Hydrocortisone

First Posted Date: 2014-01-23

Last Posted Date: 2022-05-02

Lead Sponsor: University of California, San Diego

Target Recruit Count: 31

Registration Number: NCT02043587

Locations: 🇺🇸
UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center, La Jolla, California, United States
🇺🇸
Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 1 locations

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphobkastic Leukemia

Interventions: Drug: Vincristine
Drug: Daunorubicin
Drug: Prednisone
Drug: L-asparaginase
Drug: Ciclophosphamide
Drug: Metotrexate
Drug: ARA-C
Drug: Hidrocortisone
Drug: Mercaptopurine
Drug: VP-16
Drug: Dexametasone

First Posted Date: 2014-01-15

Last Posted Date: 2020-03-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 107

Registration Number: NCT02036489

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Barcelona, Spain

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia-2
Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Etoposide
Drug: Idarubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Pomalidomide

First Posted Date: 2014-01-08

Last Posted Date: 2020-10-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT02029950

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Phase 1

Completed

Conditions: B-Cell Malignancies

Interventions: Drug: Parsaclisib
Drug: Itacitinib
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2013-12-23

Last Posted Date: 2023-09-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 88

Registration Number: NCT02018861

Locations: 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
🇺🇸
Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

and more 4 locations

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Phase 2

Completed

Conditions: Medulloblastoma With Extensive Nodularity
Medulloblastoma
Nevoid Basal Cell Carcinoma Syndrome
Desmoplastic/Nodular Medulloblastoma

Interventions: Drug: Carboplatin
Other: Cognitive Assessment
Drug: Cyclophosphamide
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Vincristine Sulfate

First Posted Date: 2013-12-23

Last Posted Date: 2023-01-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 26

Registration Number: NCT02017964

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 170 locations

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Not Applicable

Conditions: Recurrent Childhood Brain Tumor

Interventions: Device: Tumor biology testing
Drug: Temozolomide
Drug: Etoposide
Drug: Everolimus
Drug: Erlotinib
Drug: Dasatinib
Drug: Sorafenib

First Posted Date: 2013-12-19

Last Posted Date: 2016-12-15

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 20

Registration Number: NCT02015728

Locations: 🇺🇸
Seattle Children's, Seattle, Washington, United States

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Etoposide
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
Drug: Vincristine Sulfate
Procedure: X-Ray Imaging

First Posted Date: 2013-12-06

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 488

Registration Number: NCT02003222

Locations: 🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸
Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸
Banner McKee Medical Center, Loveland, Colorado, United States

and more 545 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy